Method for stimulating T cell response against lymphoblastic leukemia with leukemia tumor specific antigens
AssigneeUniversite de Montreal
InventorsClaude Perreault, Pierre Thibault, Marie-Pierre Hardy
Life of this patent
Estimating the term…
Abstract
Acute lymphoblastic leukemia (ALL) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) specifically expressed by ALL cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells, antibodies and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, antibodies, cells and vaccines for the treatment of leukemia such as ALL is also described.
Claims12
A method of stimulating a T cell response against lymphoblastic leukemia in a subject comprising administering to the subject an effective amount of:
- (i) a leukemia tumor antigen peptide (TAP) comprising the amino acid sequence of SEQ ID NO:4;
- or a nucleic acid encoding said TAP;
- (ii) a combination comprising of the leukemia TAP or nucleic acid defined in (i), and at least one additional leukemia TAP or nucleic acid encoding the at least one additional leukemia TAP, wherein the at least one additional leukemia TAP comprises one of the amino acid sequences set forth in SEQ ID NOs:
- 1-3, 5-88 and 92;
- (iii) a vehicle comprising the leukemia TAP or nucleic acid defined in (i), or the combination defined in (ii);
- (iv) a composition comprising the leukemia TAP or nucleic acid defined in (i), the combination defined in (ii);
- or the vehicle defined in (iii);
- or
- (v) a vaccine comprising the leukemia TAP or nucleic acid defined in (i), the combination defined in (ii);
- the vehicle defined in (iii) or the composition defined in (iv);
- and an adjuvant.
Dependencies are inferred from the claim text.